Chemotherapeutically induced cutaneous tuberculosis after BCG injection in a patient with pelvic osteosarcoma

Giovanni Zoccali, Carlo Cota, Giulio Marolda, Virginia Ferraresi, Maurizio Giuliani, Carmine Zoccali

Research output: Contribution to journalArticlepeer-review


Background: Tuberculosis (TB) is a serious infection afflicting a multitude of people worldwide. Recently, its prevalence has increased. The incidence of skin involvement generally is low. Bacillus Calmette-Guérin (BCG) is a live attenuated strain of Mycobacterium bovis that typically is administered as a vaccine to stimulate the immune system when treating some early neoplasms or to guard against tuberculosis. Methods: Case report and literature review. Case Report: The authors describe a young man with osteosarcoma of the left hemipelvis who received intradermal BCG injection for immune stimulation prior to surgery. In the course of neoadjuvant chemotherapy, he developed cutaneous tuberculosis. Conclusion: It is our opinion that BCG injection should be avoided in all patients requiring surgery, especially in oncologic patients, where the immunodeficiency brought on by chemotherapy predisposes to active opportunistic infection.

Original languageEnglish
Pages (from-to)406-408
Number of pages3
JournalSurgical Infections
Issue number6
Publication statusPublished - Dec 1 2012

ASJC Scopus subject areas

  • Surgery
  • Infectious Diseases
  • Microbiology (medical)


Dive into the research topics of 'Chemotherapeutically induced cutaneous tuberculosis after BCG injection in a patient with pelvic osteosarcoma'. Together they form a unique fingerprint.

Cite this